Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $705000.0.

  • Tango Therapeutics' Other Non Operating Income fell 6395.71% to $705000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 4918.25%. This contributed to the annual value of $7.6 million for FY2024, which is 2804.51% up from last year.
  • Latest data reveals that Tango Therapeutics reported Other Non Operating Income of $705000.0 as of Q3 2025, which was down 6395.71% from $910000.0 recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Other Non Operating Income registered a high of $2.2 million during Q1 2024, and its lowest value of -$81000.0 during Q4 2021.
  • In the last 5 years, Tango Therapeutics' Other Non Operating Income had a median value of $967000.0 in 2022 and averaged $920421.1.
  • Per our database at Business Quant, Tango Therapeutics' Other Non Operating Income plummeted by 415000.0% in 2021 and then skyrocketed by 268936.17% in 2023.
  • Quarter analysis of 5 years shows Tango Therapeutics' Other Non Operating Income stood at -$81000.0 in 2021, then soared by 1293.83% to $967000.0 in 2022, then surged by 113.13% to $2.1 million in 2023, then decreased by 28.38% to $1.5 million in 2024, then crashed by 52.24% to $705000.0 in 2025.
  • Its last three reported values are $705000.0 in Q3 2025, $910000.0 for Q2 2025, and $1.1 million during Q1 2025.